Cargando…
Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma
BACKGROUND: Implementation of adjuvant therapies in non-metastatic melanoma improved treatment outcomes in some patients; however, adjuvant therapy can be associated with significant cost and risk of toxicity. Therefore, there is an unmet need to better identify patients at high risk of recurrence....
Autores principales: | Gouda, M.A., Polivka, J., Huang, H.J., Treskova, I., Pivovarcikova, K., Fikrle, T., Woznica, V., Dustin, D.J., Call, S.G., Meric-Bernstam, F., Pesta, M., Janku, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695283/ https://www.ncbi.nlm.nih.gov/pubmed/34942440 http://dx.doi.org/10.1016/j.esmoop.2021.100357 |
Ejemplares similares
-
Ultrasensitive Detection of BRAF Mutations in Circulating Tumor DNA of Patients With Metastatic Thyroid Cancer
por: Gouda, Mohamed A, et al.
Publicado: (2021) -
Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023) -
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers
por: Dumbrava, E.E., et al.
Publicado: (2021) -
Patients with three or more primary melanomas: clinical-epidemiological study()
por: Fikrle, Tomas, et al.
Publicado: (2023) -
BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers
por: Castellani, Giorgia, et al.
Publicado: (2023)